Vertex Reports First Quarter 2026 Financial Results
Vertex reported Q1 2026 revenue of $2.99 billion, up 8% year-over-year, with GAAP diluted EPS rising to $4.02 from $2.49 in the prior year. The company reiterated full-year 2026 guidance for total revenue of $12.95 billion to $13.1 billion, driven by leadership in cystic fibrosis and growth in sickle cell disease and acute pain.
Key figures
- Eps
- 4.02
- Revenue
- 2986900000
- Guidance
- FY2026 total revenue $12.95B-$13.1B; Non-CF product revenue $500M or greater
- Revenue Yoy
- 8%
- Cash position
- $13.0 billion
- Casgevy revenue
- 43000000
- Journavx revenue
- 29000000
AI analysis
Red flags1 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.